Compare Manchester United PLC (MANU) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Novavax Inc — how do they compare? Manchester United PLC trades at $22.8 (market cap $3.80B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Manchester United PLC is far larger — about 2.9× Novavax Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MANU | NVAX | |
|---|---|---|
Market Cap | $3.80B | $1.31B |
Sector | Media | Health |
52-Week High | $23.53 | $11.19 |
52-Week Low | $15.10 | $6.22 |
Enterprise Value | $4.74B | $889.30M |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.60, up 4.15% today, with a bearish technical signal. The company reported Q1 2026 EPS of $0.04, beating expectations, but missed in Q4 2025. Revenue trends show modest growth to $667M in 2025, though net income remains negative. Key developments include securing land for a new stadium and Champions League qualification boosting future revenue prospects.
The outlook is mixed; stadium development and cost reductions offer long-term upside, but persistent losses and high debt pose risks. Analysts are cautious with 40% buy ratings. Investment opportunity hinges on operational turnaround, while risks include weak cash flow and competitive pressures.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
